Four Abstracts by Biopure and Collaborating Scientists Accepted for Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
CAMBRIDGE, Mass., December 04, 2007 /PRNewswire-FirstCall/ -- Biopure Corporation announces the acceptance of four abstracts for presentation at the American Society for Clinical Pharmacology and Therapeutics annual meeting to be held April 2-5, 2008. The Society is the largest scientific and professional organization serving the discipline of clinical pharmacology.
These abstracts address the basis for adverse event outcomes and other key findings in previous surgical studies of Hemopure. Biopure and the collaborating scientists also address the safety and efficacy of both Hemopure and Hemoglobin-based oxygen carriers (HBOCs) in general. The titles, authors and affiliations are as follows:
RISK OF ADVERSE OUTCOME DUE TO ACUTE ANEMIA IN THE ORTHOPEDIC SURGICAL SETTING. L. B. Pearce, A. N. Pitman; Biopure Corporation, Cambridge, MA.
BREAKING THE RULES: MISINTERPRETATION OF DOSE-RESPONSE RELATIONSHIPS IN CLINICAL TRIALS. L. B. Pearce, A. N. Pitman, A. G. Greenburg; Biopure Corporation, Cambridge, MA.
A FLEXIBLE OUTCOME SCORING SYSTEM FOR CLINICAL TRIALS. A. N. Pitman, L. B. Pearce; Biopure Corporation, Cambridge, MA.
APPLICATION OF A UNIQUE SCORING SYSTEM FOR NUMERICAL DETERMINATION OF A BENEFIT RISK RATIO IN CLINICAL TRIALS. L. B. Pearce(1), A. Pitman,(1) A. G. Greenburg,(1) D. A. Freilich,(2) L. Kaplan(3); (1)Biopure Corporation, Cambridge, MA, (2)Naval Medical Research Center, Silver Spring, MD, (3)Yale University School of Medicine, New Haven, CT. WHAT ARE THE SUPERSCRIPT NUMERALS? They correspond to the institution listed to which each of the authors is affiliated.
Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. Biopure has applied in the United Kingdom for regulatory approval of a proposed orthopedic surgical anemia indication. The company is developing Hemopure for several other indications and is supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 bovine)], or HBOC-301, the only oxygen therapeutic approved by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold approximately 186,000 units of Oxyglobin.
Contact: Tiana Gorham Herb Lanzet (Investors) Biopure Corporation H.L. Lanzet Inc. (617) 234-6826 (212) 888-4570IR@biopure.com email@example.com
Web site: http://www.biopure.com/
Company News On-Call: http://www.prnewswire.com/comp/131224.html/
Ticker Symbol: (NASDAQ-NMS:BPUR)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: December 2007